SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
SARS-CoV-2 is the cause of one of the largest noninfluenza pandemics of this century. This exceptional public health crisis highlights the urgent need for better understanding of the correlates of protection from infection and severe COVID-19.
Article activity feed
-
-
SciScore for 10.1101/2022.03.28.22273068: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The study protocol was reviewed and approved by the Mount Sinai Hospital Institutional Review Board (IRB-20-03374).
Consent: All participants provided written informed consent.Sex as a biological variable Sex (female, male), age (<40 years, 40+ years), and baseline titer (<1:800, ≥1:800) were included as covariates in the model, along with a random intercept for participant ID to account for repeated measures. Randomization Sex (female, male), age (<40 years, 40+ years), and baseline titer (<1:800, ≥1:800) were included as covariates in the model, along with a random intercept for participant ID to account for repeated measures. Blinding not detected. Power Analysis not detected. Table 2: …
SciScore for 10.1101/2022.03.28.22273068: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The study protocol was reviewed and approved by the Mount Sinai Hospital Institutional Review Board (IRB-20-03374).
Consent: All participants provided written informed consent.Sex as a biological variable Sex (female, male), age (<40 years, 40+ years), and baseline titer (<1:800, ≥1:800) were included as covariates in the model, along with a random intercept for participant ID to account for repeated measures. Randomization Sex (female, male), age (<40 years, 40+ years), and baseline titer (<1:800, ≥1:800) were included as covariates in the model, along with a random intercept for participant ID to account for repeated measures. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources The data of 813 distinct study visits from these 137 seropositive participants provide the basis for the modeling SARS-CoV-2 spike-binding IgG antibody durability. SARS-CoV-2 spike-binding IgGsuggested: NonePlates were washed three times with PBS-T and 50 μl/well of anti-human IgG (Fab-specific) horseradish peroxidase antibody (produced in goat; Sigma, A0293) diluted to 1:3,000 in PBS-T, 1% milk powder, were added to each well. anti-human IgGsuggested: (Sigma-Aldrich Cat# A0293, RRID:AB_257875)A0293suggested: NoneSoftware and Algorithms Sentences Resources Endpoint titers, expressed as the last dilution before the signal dropped below an OD490nm of 0.15, were calculated in excel and data was plotted using GraphPad Prism 9. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:This analysis did, however, also have a few limitations. First, since we started enrollment during the first wave, a good portion of participants were unable to get molecular tests at the time of infection and we relied on retrospective reports of clinical signs and symptoms suggestive of COVID-19 for illness onset date. As such, recall bias in reported illness onset is a possibility. However, we anticipate that this exerted only a minor impact on our conclusions given the relatively homogenous exposures of participants who are all health care workers. Second, with healthcare worker vaccination beginning in December 2020 we were unable to effectively assess how circulating variants of concern may affect one’s risk of re-infection following natural infection. The increase in vaccinated participants (excluded from this analysis), while fortunate, also resulted in a smaller sample size at the end of the follow-up period extending into August 2021. In conclusion, our study shows that SARS-CoV-2 infection provides strong protection from reinfection and this protection may be associated with the presence of spike binding antibodies. In addition, it suggests that antibody levels induced by infection with ancestral SARS-CoV-2 variants are relatively stable over time and that the rate of seroreversion is low when measuring SARS-CoV-2 spike binding IgG antibodies.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
